InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,011.12
(
-0.22%
)
US TECH 100
16,870.80
(
-0.39%
)
Dow Jones
37,775.38
(
0.00%
)
Brent Oil
86.02
(
-0.46%
)
Bitcoin
65,153.91
(
2.59%
)
Post# of 174
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

conix

Send PM Follow Ignore
Followers 224
Posts 31777
Boards Moderated 4
Alias Born 10/10/2005

conix

Re: deri21 post# 100

Thursday, 06/10/2021 2:13:36 PM

Thursday, June 10, 2021 2:13:36 PM

Post# of 174
In the second half of 2021, Acer intends to submit a protocol for the prospective study, along with an investigational new drug application (IND), request breakthrough therapy designation, and coordinate with FDA to reach agreement on a Special Protocol Assessment (SPA).

Based on initial power calculations, Acer anticipates that the trial should enroll approximately 200 COL3A1+ vEDS patients in the U.S., and the duration of the clinical trial is estimated to be approximately 3.5 years to complete once fully enrolled.

Successful Trading is the art of minimizing long term risk and maximizing capital allocation.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up